| Abstract: | The British Medicines Commission has undertaken an urgent review of arrangements for testing new drugs on healthy volunteers in the wake of charges that one company, Charterhouse Clinical Research Unit Ltd., was using London students in toxicity tests of an antitumor drug without having informed the volunteers' physicians of the risks involved and without plans for long-term monitoring of the participants' health. Under current British law, drug studies with healthy volunteers are regarded as a private matter between the volunteers and the drug companies, which vary in their practices on disclosure of risks and compensation for injuries. |
